Table 2. HIV and ARV-related characteristics for youth with perinatal HIV infection.
| Characteristic | Total perinatally HIV-infected (N = 231) | |
|---|---|---|
| Measures of past disease severity | ||
| Nadir CD4 %, median (IQR) | 19 (12, 25) | |
| Age at nadir CD4 %, yrs, median (IQR) | 3.40 (1.50, 8.10) | |
| Peak HIV RNA viral load (log10 copies/mL), median (IQR) | 5.67 (5.10, 5.88) | |
| Age at peak viral load, yrs, median (IQR) | 1.80 (0.40, 4.70) | |
| CDC Class C (AIDS-defining diagnosis), N (%) | 56 (24 %) | |
| HIV-related encephalopathy prior to entry, N (%) | 19 (8 %) | |
| Age at HAART initiationa (yrs), median (IQR) | 2.20 (0.60, 4.90) | |
| Measures of disease severity at study entry | ||
| Entry CD4 %, median (IQR) | 34 (28, 39) | |
| Entry RNA viral loada (log10 copies/mL), median (IQR) | 2.34 (1.70, 2.63) | |
| Entry HIV RNA <400 copies/mL | 171 (75 %) | |
| ARV regimen at entry, N (%) | HAART with PI | 162 (70 %) |
| HAART without PI | 38 (16 %) | |
| Non-HAART ARV | 19 (8 %) | |
| Not on ARV | 12 (5 %) | |
ARV antiretroviral, CDC centers for disease control and prevention, IQR interquartile range (25th percentile, 75th percentile), HAART highly active antiretroviral therapy (defined as at least 3 ARV drugs from at least 2 drug classes), PI protease inhibitor
a
2 participants had no available viral load measures within 6 months prior to study entry; age at HAART initiation was not available for 3 participants